Cover Image
Market Research Report

Inclusion Body Myositis (IBM) - Pipeline Review, H1 2020

Published by Global Markets Direct Product code 271829
Published Content info 70 Pages
Delivery time: 1-2 business days
Price
Back to Top
Inclusion Body Myositis (IBM) - Pipeline Review, H1 2020
Published: April 30, 2020 Content info: 70 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Inclusion Body Myositis - Pipeline Review, H1 2020, provides an overview of the Inclusion Body Myositis (Musculoskeletal Disorders) pipeline landscape.

Inclusion Body Myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated tissues, such as the blood vessels that supply the muscles. IBM symptoms include progressive weakness of the muscles of the wrists and fingers, the muscles of the front of the thigh, and the muscles that lift the front of the foot.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Inclusion Body Myositis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Inclusion Body Myositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Inclusion Body Myositis (IBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 1, 5 and 1 respectively.

Inclusion Body Myositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Inclusion Body Myositis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Inclusion Body Myositis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Inclusion Body Myositis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Inclusion Body Myositis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Inclusion Body Myositis (Musculoskeletal Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Inclusion Body Myositis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Inclusion Body Myositis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC12155IDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Inclusion Body Myositis (IBM) - Overview
    • Inclusion Body Myositis (IBM) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Inclusion Body Myositis (IBM) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Inclusion Body Myositis (IBM) - Companies Involved in Therapeutics Development
    • AAVogen Inc
    • Abcuro Inc
    • Alzheon Inc
    • Cleave Therapeutics Inc
    • Kv1.3 Therapeutics
    • Leadiant Biosciences Inc
    • Milo Biotechnology LLC
    • Nobelpharma Co Ltd
    • Orphazyme A/S
    • PhaseBio Pharmaceuticals Inc
    • Ultragenyx Pharmaceutical Inc
  • Inclusion Body Myositis (IBM) - Drug Profiles
    • ABC-08 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aceneuramic acid ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALZ-507 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • arimoclomol citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVGN-7 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dalazatide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DEXM-74 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene therapy To Activate Follistatin For Duchenne Muscular Dystrophy, Becker Muscular Dystrophy And Inclusion Body Myositis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PB-1023 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit VCP/p97 for Neurodegenerative Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UX-001P - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Inclusion Body Myositis (IBM) - Dormant Projects
  • Inclusion Body Myositis (IBM) - Discontinued Products
  • Inclusion Body Myositis (IBM) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 11, 2020: CytRx highlights recently published data of its licensee Orphazyme A/S Phase 2 trial of Arimoclomol in the treatment of Sporadic Inclusion Body Myositis (sIBM)
      • Dec 18, 2019: Orphazyme's arimoclomol receives US fast track designation in sporadic inclusion body myositis
      • May 02, 2019: CytRx Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme
      • Apr 29, 2019: CytRx highlights enrollment completion in phase 2/3 clinical trial of Sporadic Inclusion Body Myositis conducted by Arimoclomol Licensee Orphazyme
      • Apr 23, 2019: Orphazyme's Phase II/III trial in sporadic Inclusion Body Myositis fully enrolled
      • Apr 25, 2018: New Data Supports Dalazatide from Kv 1.3 Therapeutics as a Potential Therapy for Inclusion Body Myositis
      • Dec 14, 2017: Orphazyme Assumes Sponsorship of Phase II/III sIBM Trial
      • Nov 07, 2017: Orphazyme Receives Orphan Drug Designation To Arimoclomol For Inclusion Body Myositis From The U.S. FDA
      • Aug 22, 2017: Ultragenyx Announces Top-Line Results from Phase 3 Study of Ace-ER in GNE Myopathy
      • Nov 11, 2016: Ultragenyx Announces Withdrawal of Marketing Authorization Application for Aceneuramic Acid Prolonged Release (Ace-ER) in the European Union
      • Jul 27, 2016: Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy
      • Mar 24, 2016: Arimoclomol shows promise in protein misfolding disease
      • Mar 23, 2016: New drug shows promise against muscle wasting disease
      • Oct 02, 2015: Ultragenyx Announces Aceneuramic Acid Prolonged Release Marketing Authorization Application Filed and Accepted for Review by European Medicines Agency
      • May 28, 2015: Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of Aceneuramic Acid (Sialic Acid) Extended Release in GNE Myopathy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Inclusion Body Myositis (IBM), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by AAVogen Inc, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by Abcuro Inc, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by Alzheon Inc, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by Cleave Therapeutics Inc, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by Kv1.3 Therapeutics, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by Leadiant Biosciences Inc, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by Milo Biotechnology LLC, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by Nobelpharma Co Ltd, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by Orphazyme A/S, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by PhaseBio Pharmaceuticals Inc, H1 2020
  • Inclusion Body Myositis (IBM) - Pipeline by Ultragenyx Pharmaceutical Inc, H1 2020
  • Inclusion Body Myositis (IBM) - Dormant Projects, H1 2020
  • Inclusion Body Myositis (IBM) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Inclusion Body Myositis (IBM), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Back to Top